MiRXES announced today that it has launched Project CADENCE (CAncer Detected Early caN be CurEd), the world’s first large-scale clinical research project for the discovery and validation of novel combinations blood-borne circulating microRNA (miRNA) and DNA methylation biomarkers that will lead to the development of a multi-cancer early detection test for up to nine high incidence and high mortality cancers.

MiRXES has opened the first industry 4.0 (i4.0) in vitro diagnostic (IVD) manufacturing facility in Southeast Asia. This S$8 million facility at JTC MedTech Hub is the largest i4.0 IVD manufacturing site at in Southeast Asia at 15,000 square feet.

MiRXES announced today that Dr. Lihan ZHOU, Co-founder and Chief Executive Officer at MiRXES, Dr. Ruiyang ZOU, Co-founder and Chief Technology Officer at MiRXES and Mr. Isaac HO, Chief Investment Officer at MiRXES, have been named EY Entrepreneur Of The Year (EOY) 2021 Singapore by professional services organization, EY.